Understanding how DNA stress in kidney cancer affects immunotherapy success

Determining the Immunological Consequences of DNA Replication Stress Response Defects in Renal Cells Carcinoma to Improve Immunotherapy Outcomes

NIH-funded research Cleveland Clinic Lerner Com-Cwru · NIH-10893543

This study is looking at how certain problems with DNA copying in kidney cancer might affect how well immunotherapy works, with the hope of finding a gene signature that can help predict which patients will benefit most from treatment.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionCleveland Clinic Lerner Com-Cwru NIH-funded
Lab location1 site (Cleveland, United States)
Project IDNIH-10893543 on NIH RePORTER

What this research studies

This research investigates the role of DNA replication stress response defects in renal cell carcinoma (RCC) and how these defects may influence the effectiveness of immunotherapy. The study aims to identify a specific gene signature associated with these defects that could predict patient responses to treatment. By using advanced imaging techniques and genetically engineered mouse models, researchers will explore the immune environment and the mechanisms by which these defects enhance sensitivity to immunotherapy. The ultimate goal is to improve treatment outcomes for patients with RCC who currently have limited options.

Who could benefit from this research

Good fit: Ideal candidates for this research are patients diagnosed with renal cell carcinoma, particularly those who have not responded well to existing immunotherapy treatments.

Not a fit: Patients with renal cell carcinoma who have already shown a positive response to immunotherapy may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to more effective immunotherapy strategies for patients with renal cell carcinoma.

How similar studies have performed: Previous research has shown promise in using genetic signatures to predict immunotherapy responses, suggesting that this approach may yield valuable insights.

Where this research is happening

Cleveland, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Breast CancerCancersCandidate Disease Gene
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.